Adenocarcinoma

Chemotherapy

Platinum-based

Cisplatin

Carboplatin

Nedaplatin

Alkaloids

Vinorelbine ditartrate

Paclitaxel

Docetaxel

Antimetabolites

Pemetrexed

Gemcitabine

TOPO Inhibitors

Irinotecan

RET-Targeted

Selective RET Inhibitors

Selpercatinib

Pralsetinib

Non-Selective RET Inhibitors

Cabozantinib

Vandetanib

Lenvatinib

Regorafenib

BRAF-Targeted

First-Generation (Type I) BRAF Inhibitors

Vemurafenib

Dabrafenib

Encorafenib

Next-Generation (Type II) BRAF Inhibitors

AZ 628

LY3009120

ROS1-Targeted

First-Generation ROS1-TKIs

Crizotinib

Second-Generation ROS1-TKIs

Ceritinib

Repotrectinib

Third-Generation ROS1-TKIs

Lorlatinib 

MET-Targeted

Type I MET-TKIs

Crizotinib

Capmatinib

Tepotinib

Savolitinib

Type II MET-TKIs

Cabozantinib

Merestinib

Type III MET-TKIs

Tivantinib

KRAS G12C-Targeted

ALK-Targeted

First-Generation ALK-TKIs

Crizotinib

Second-Generation ALK-TKIs

Ceritinib

Alectinib

Brigatinib

Ensartinib dihydrochloride

Third-Generation ALK-TKIs

Lorlatinib 

EGFR-Targeted

First-Generation EGFR-TKIs

Erlotinib

Gefitinib

Lapatinib

Icotinib

Second-Generation EGFR-TKIs

Afatinib

Dacomitinib

Neratinib

Poziotinib

Third-Generation EGFR-TKIs

Osimertinib

Mobocertinib

Rociletinib

Olmutinib

Nazartinib

Alflutinib mesylate

Almonertinib

Lazertinib

Fourth-Generation EGFR-TKIs

EAI045

Anti-EGFR Antibodies

Cetuximab

Panitumumab

Necitumumab

Compound Library

ADC

c-Met

Telisotuzumab vedotin

HER2

Trastuzumab-Emtansine

Trastuzumab-deruxtecan

HER3

Patritumab deruxtecan

Anti-Angiogenesis

Immune Checkpoint Inhibitors

PD-1

Pembrolizumab

Camrelizumab

Sintilimab

Nivolumab

Cemiplimab

PD-L1

Atezolizumab

Durvalumab

Avelumab

CTLA-4

Ipilimumab

Tremelimumab

HER2-Targeted

Pan-HER TKIs

Afatinib

Neratinib

Dacomitinib

Selective HER2 TKIs

Pyrotinib dimaleate

Poziotinib

Sunvozertinib

Anti-HER2 Antibodies

Trastuzumab

Pertuzumab